A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients

Detalhes bibliográficos
Autor(a) principal: Lanzafame,Massimiliano
Data de Publicação: 2011
Outros Autores: Bonora,Stefano, Lattuada,Emanuela, Calcagno,Andrea, Vento,Sandro
Tipo de documento: Relatório
Idioma: eng
Título da fonte: Brazilian Journal of Infectious Diseases
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000500017
Resumo: Darunavir (DRV) is an HIV-1 protease inhibitor that is used together with a low boosting dose of ritonavir as part of an antiretroviral therapy (ART) regimen in treatment-experienced and naïve HIVpositive patients. In naïve and experienced patients with no DRV-mutations, DRV is licensed at the dose of 800 mg plus 100 mg of ritonavir once daily. We report our results in seven ART-experienced HIV-infected patients, in whom a reduced dose of darunavir/ritonavir (600/100 mg once daily) successfully controlled viral replication
id BSID-1_40779f520c5fbacd69233768a69b4d07
oai_identifier_str oai:scielo:S1413-86702011000500017
network_acronym_str BSID-1
network_name_str Brazilian Journal of Infectious Diseases
repository_id_str
spelling A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patientsHIV infectionspharmacokinetics antiretroviral therapyhighly activeDarunavir (DRV) is an HIV-1 protease inhibitor that is used together with a low boosting dose of ritonavir as part of an antiretroviral therapy (ART) regimen in treatment-experienced and naïve HIVpositive patients. In naïve and experienced patients with no DRV-mutations, DRV is licensed at the dose of 800 mg plus 100 mg of ritonavir once daily. We report our results in seven ART-experienced HIV-infected patients, in whom a reduced dose of darunavir/ritonavir (600/100 mg once daily) successfully controlled viral replicationBrazilian Society of Infectious Diseases2011-10-01info:eu-repo/semantics/reportinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000500017Brazilian Journal of Infectious Diseases v.15 n.5 2011reponame:Brazilian Journal of Infectious Diseasesinstname:Brazilian Society of Infectious Diseases (BSID)instacron:BSID10.1590/S1413-86702011000500017info:eu-repo/semantics/openAccessLanzafame,MassimilianoBonora,StefanoLattuada,EmanuelaCalcagno,AndreaVento,Sandroeng2011-10-17T00:00:00Zoai:scielo:S1413-86702011000500017Revistahttps://www.bjid.org.br/https://old.scielo.br/oai/scielo-oai.phpbjid@bjid.org.br||lgoldani@ufrgs.br1678-43911413-8670opendoar:2011-10-17T00:00Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)false
dc.title.none.fl_str_mv A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
title A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
spellingShingle A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
Lanzafame,Massimiliano
HIV infections
pharmacokinetics antiretroviral therapy
highly active
title_short A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
title_full A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
title_fullStr A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
title_full_unstemmed A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
title_sort A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
author Lanzafame,Massimiliano
author_facet Lanzafame,Massimiliano
Bonora,Stefano
Lattuada,Emanuela
Calcagno,Andrea
Vento,Sandro
author_role author
author2 Bonora,Stefano
Lattuada,Emanuela
Calcagno,Andrea
Vento,Sandro
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Lanzafame,Massimiliano
Bonora,Stefano
Lattuada,Emanuela
Calcagno,Andrea
Vento,Sandro
dc.subject.por.fl_str_mv HIV infections
pharmacokinetics antiretroviral therapy
highly active
topic HIV infections
pharmacokinetics antiretroviral therapy
highly active
description Darunavir (DRV) is an HIV-1 protease inhibitor that is used together with a low boosting dose of ritonavir as part of an antiretroviral therapy (ART) regimen in treatment-experienced and naïve HIVpositive patients. In naïve and experienced patients with no DRV-mutations, DRV is licensed at the dose of 800 mg plus 100 mg of ritonavir once daily. We report our results in seven ART-experienced HIV-infected patients, in whom a reduced dose of darunavir/ritonavir (600/100 mg once daily) successfully controlled viral replication
publishDate 2011
dc.date.none.fl_str_mv 2011-10-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/report
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format report
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000500017
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000500017
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1413-86702011000500017
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
dc.source.none.fl_str_mv Brazilian Journal of Infectious Diseases v.15 n.5 2011
reponame:Brazilian Journal of Infectious Diseases
instname:Brazilian Society of Infectious Diseases (BSID)
instacron:BSID
instname_str Brazilian Society of Infectious Diseases (BSID)
instacron_str BSID
institution BSID
reponame_str Brazilian Journal of Infectious Diseases
collection Brazilian Journal of Infectious Diseases
repository.name.fl_str_mv Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)
repository.mail.fl_str_mv bjid@bjid.org.br||lgoldani@ufrgs.br
_version_ 1754209241959235584

Registros relacionados